A Registry Study of Biomarkers in Heart Valve Disease - Trial NCT06223906
Access comprehensive clinical trial information for NCT06223906 through Pure Global AI's free database. This phase not specified trial is sponsored by Beijing Institute of Heart, Lung and Blood Vessel Diseases and is currently Recruiting. The study focuses on Cardiovascular Diseases. Target enrollment is 200000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Beijing Institute of Heart, Lung and Blood Vessel Diseases
Timeline & Enrollment
N/A
Jan 01, 2016
Jan 01, 2030
Primary Outcome
All-cause death
Summary
Valvular Heart Disease, impacting 2.5% of the population, is predominantly observed in the
 elderly and is on the rise. The primary conditions within this category are Aortic Stenosis
 and Mitral Regurgitation. These conditions are linked to considerable morbidity and
 mortality, presenting a formidable challenge in optimizing treatment strategies.
 Pathophysiology of Valvular Heart Disease remains poorly known. The aim of the present study
 is to identify biomarkers involved in this disease using multi-omics approaches
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06223906
Non-Device Trial